FDA Warns Soon-Shiong's ImmunityBio Over Anktiva Claims
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The FDA issued a March 13 warning letter to ImmunityBio — primarily owned and controlled by billionaire biotech figure Patrick Soon-Shiong — flagging false and misleading promotional claims about the cancer therapy Anktiva
- Anktiva, which is approved for a specific type of bladder cancer, was promoted in TV ads and a podcast as a treatment for "all cancers," a claim the agency said the approved indication does not support
- ImmunityBio's ads and podcast omitted material facts, most notably that Anktiva must be administered in combination with a vaccine, according to the warning letter
- The FDA found that risks associated with Anktiva were downplayed in the television ad and never mentioned at all in the podcast
- Both promotional channels indicated that patients treated with Anktiva would be "cancer free," a claim the FDA said is not supported by clinical studies
- Soon-Shiong is described in the source as a controversial figure in the biotech industry, a framing that contextualizes the agency's unusually pointed criticism
Why it matters: A formal FDA warning letter over cancer-drug marketing signals potential enforcement risk for ImmunityBio and its majority owner, Patrick Soon-Shiong, and could chill Anktiva's commercial rollout. The letter's specifics — unapproved broad-cancer claims, omitted vaccine-combination requirement, and unsubstantiated "cancer free" language — give the company a defined list of promotional changes to make or face further action.
Ask SkimNews
